|
SILVER SPONSORs
BEIGENE LTD.BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azaciditine) in China under a license from Celgene Corporation.
www.beigene.com |
|
BRISTOL-MYERS SQUIBBBristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. We have built a sustainable pipeline of potential therapies, and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient at the right time to achieve the best outcome.
Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do. www.bms.com |
|
EIT HealthEIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.
https://www.eithealth.eu/web/internet-eithealth |
|
Italian Trade Agency (ITA)Italian Trade Agency (ITA) is a governmental body promoting the connectivity between Italian tech-clusters and international partners. In the field of Health-Biotech, ITA promotes transnational cooperation in manufacturing and R&D. This is achieved by supporting match-making in Italy, and through ITA’s 80 world-wide offices also internationally. ITA serves as a one-stop window for international companies requiring support in doing business in Italy.
www.ice.it |
|
TORREYA PARTNERS LLPTorreya is a global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
www.torreya.com |
|
CONTRIBUTING SPONSORs
Abingworth LLPAbingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.
Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Our specialist team of over 20 professionals has a broad range of skills, including scientific and business expertise as well as investment banking, recruitment and legal knowledge. These resources are made available to portfolio companies. Abingworth has funds under management of over $1.1 billion and offices in London, Menlo Park (California) and Boston. https://www.abingworth.com |
|
BIOMEDPARTNERS AGBioMedPartners AG is a Basel-based Life Science Venture Capital Firm that invests in innovative private early- to mid-stage human Life Science companies in Switzerland and surrounding EU countries. It has recently raised a new fund, BioMedInvest-III LP, at CHF 100 million, and has now a total of CHF 350 million under management.
www.biomedvc.com |
|
Locust WalkLocust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and medtech companies.
www.locustwalk.com |
|
NOVO HOLDINGS A/SNovo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is the holding company in the Novo Group, responsible for the management of the assets of the Novo Nordisk Foundation, which are currently valued at more than USD 30 billion. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies, within life science and biotechnology, as well as manages a broad portfolio of financial assets.
www.novoholdings.dk |
|
Staatz Business Development & StrategyStaatz Business Development & Strategy is a consulting firm with two complementary fields of expertise: business development and market access.
Our Senior Consultant team identifies and secures on a global basis for our international clients strategic partnering options on the buy and the sell side, applying our scientific and commercial expertise, vast network and profound process management. Our deals range from worldwide to national agreements and cover all deal structures customary in our industry, including M&A. Our track-record, comprising successful transactions in many indication areas with a transaction value to date exceeding US$ 3 bn in total is based on our successful preparation, our efficient and structured operational management and skilled negotiation. We also advise clients from the international industry on market access and pricing & reimbursement strategies and processes for European markets. We have successfully developed and implemented Market Access Strategies including the development and testing of value messages, preparation of value dossiers, provision of pricing and reimbursement assessment and negotiation support. www.staatz.biz |
|
Syneos HealthSyneos Health™ is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together to create customer success. Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum. Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.
https://www.syneoshealth.com/ |
|